FDA approves rusfertide (Mimrylo), a peptide hepcidin mimetic, for polycythemia vera

On August 28, 2026, FDA approved Takeda's Mimrylo (rusfertide), a synthetic cyclic peptide that mimics hepcidin, for erythrocytosis in adults with polycythemia vera.

Basics4 min read

Key takeaway

Mimrylo (rusfertide) is approved “for the treatment of erythrocytosis in adults with polycythemia vera (PV)”. FDA says it mimics hepcidin, a hormone that regulates iron. FDA cites the phase 3 VERIFY trial of 293 adults. It received priority review and carries an orphan designation dating from June 12, 2020.

At a glance

Article typeBasics
Main guideRusfertide: complete guide
Regulatory statusFDA-approved“FDA approved rusfertide as Mimrylo on August 28, 2026.” (Rusfertide: complete guide)
ClassHeart & blood
Body systemsHeart & vessels
Studies cited0 in this article · 2 across 2 articles on Rusfertide
Related productsResearch peptide catalog

FDA approved rusfertide, sold as Mimrylo, on August 28, 2026. The agency announced the approval for Takeda Pharmaceuticals America, Inc. under the headline “FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder.” The approved label describes rusfertide as “a synthetic cyclic peptide,” which makes this a new peptide drug approval. It is number 36 on FDA’s list of novel drug approvals for 2026.

Quick answer: What did FDA approve? A new peptide medicine, rusfertide (Mimrylo), for erythrocytosis in adults with polycythemia vera, a rare blood disorder. It is a prescription drug with a single approved use. The approval does not change how any other peptide is regulated.

This article summarizes public regulatory records. It is not medical or legal advice.

What did FDA approve?

FDA’s novel approvals list records Mimrylo (rusfertide) as approved on August 28, 2026, “to treat erythrocytosis in adults with polycythemia vera” (FDA, 2026a). FDA’s announcement names Takeda Pharmaceuticals America, Inc. as the company granted approval and says the drug “mimics hepcidin,” limiting the iron available for making new red blood cells (FDA, 2026b).

The prescribing information gives the chemistry. Its description section calls rusfertide “a hepcidin mimetic” that “is a synthetic cyclic peptide (disulfide)” isolated as an acetate salt. Its mechanism section says rusfertide “is a mimetic of the endogenous hormone hepcidin that blocks the iron transporter ferroportin” (Takeda, 2026).

Table 1

Mimrylo (rusfertide) approval at a glance

Item Detail
Approval date August 28, 2026
Company Takeda Pharmaceuticals America, Inc.
Indication Erythrocytosis in adults with polycythemia vera
Molecule Synthetic cyclic peptide, hepcidin mimetic
Pivotal trial VERIFY, phase 3, 293 adults, 32 weeks
Review Priority review
Orphan designation Designated June 12, 2020; exclusivity end date listed as TBD

What evidence supported the approval?

FDA cites VERIFY, a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. It enrolled 293 adults who needed frequent phlebotomies, a procedure to remove blood, despite standard care. Patients were randomized one to one to Mimrylo or placebo over 32 weeks. The efficacy measure was the share of patients who did not meet criteria for phlebotomy between weeks 20 and 32. FDA reports 76.9% for Mimrylo and 32.9% for placebo (FDA, 2026b).

FDA lists injection site reactions and anemia as the most common side effects. The label’s warnings and precautions cover new or worsening thrombocytosis, a rise in blood platelets; injection-site reactions; and embryo-fetal toxicity (Takeda, 2026). Tanya Wroblewski, M.D., director of FDA’s Division of Nonmalignant Hematology, called it a “first-in-class option that has the potential to meaningfully reduce patient burden.”

What does it change, and what does it not change?

It adds an approved treatment for erythrocytosis in polycythemia vera that works by mimicking hepcidin, which FDA describes as a first of its kind. FDA’s orphan drug database lists the marketing approval on August 28, 2026, with the exclusivity end date still shown as “TBD” (FDA, 2026c).

It does not change the rules for other peptides. Approval covers one product, one sponsor and one indication. It does not affect compounding lists, research-use sales or any other compound’s status.

Who does it affect?

Prescribers and patients: clinicians treating polycythemia vera now have a prescription option in this new class. Takeda: the sponsor and orphan designation holder. Compounders, sellers and researchers: not addressed by the approval.

How does it fit the earlier history?

FDA granted rusfertide orphan designation for the treatment of polycythemia vera on June 12, 2020, to Takeda Development Center Americas, Inc. (FDA, 2026c). It is not the only peptide on FDA’s 2026 list. On July 15, 2026, FDA approved Lipfendra (enlicitide decanoate) to reduce LDL cholesterol; its label describes enlicitide as “a macrocyclic peptide that binds to PCSK9” (Merck, 2026). For background on peptide medicines, see peptide hormones, types of peptides and peptides and the FDA in 2026.

Frequently asked questions about the rusfertide approval

Is rusfertide a peptide?

Yes. Its FDA-approved label describes it as a synthetic cyclic peptide (disulfide) and a hepcidin mimetic.

What is Mimrylo approved for?

The treatment of erythrocytosis in adults with polycythemia vera.

When was it approved, and for which company?

August 28, 2026, for Takeda Pharmaceuticals America, Inc.

What to know now

  • Approval: Mimrylo (rusfertide), August 28, 2026, novel drug approval number 36 of 2026.
  • Use: erythrocytosis in adults with polycythemia vera.
  • Molecule: synthetic cyclic peptide that mimics hepcidin.
  • Evidence: phase 3 VERIFY trial, 293 adults.

What we’re watching

Label updates for Mimrylo, the orphan exclusivity end date once FDA lists it, and further peptide drug approvals on FDA’s novel approvals list.

Also in the library

More for heart & vessels

All 13 compounds for heart & vessels

Sources: U.S. Food and Drug Administration 2026a, Novel drug approvals for 2026; U.S. Food and Drug Administration 2026b, FDA approves first drug of its kind for polycythemia vera, a rare blood disorder; U.S. Food and Drug Administration 2026c, Search orphan drug designations and approvals: rusfertide; Takeda Pharmaceuticals America 2026, MIMRYLO (rusfertide) for injection: prescribing information; Merck Sharp & Dohme LLC 2026, LIPFENDRA (enlicitide) tablets: prescribing information. All 5 citations

Back to the research library

References

  1. U.S. Food and Drug Administration. (2026a). Novel drug approvals for 2026 (content current as of November 16, 2026). https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
  2. U.S. Food and Drug Administration. (2026b, August 28). FDA approves first drug of its kind for polycythemia vera, a rare blood disorder [Press announcement]. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder
  3. U.S. Food and Drug Administration. (2026c). Search orphan drug designations and approvals: rusfertide. Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=715819
  4. Takeda Pharmaceuticals America, Inc. (2026). MIMRYLO (rusfertide) for injection: prescribing information (revised August 2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=101aff01-31ed-4841-a8b6-0a5a8503189b
  5. Merck Sharp & Dohme LLC. (2026). LIPFENDRA (enlicitide) tablets: prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=enlicitide